Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Seres Therapeutics Temettü

Temettü kriter kontrolleri 0/6

Seres Therapeutics şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

n/a

Ödeme oranı

Sektör ortalama getirisi	1.9%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Hisse başına kazanç	-US$1.06
Temettü verim tahmini	0%

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Seres Therapeutics' Strategic Sale Of Vowst Warrants A Rating Upgrade

Sep 23

Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 44% But Investors Aren't Buying For Growth

Jul 13

Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 46% But Investors Aren't Buying For Growth

May 08

Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet

Mar 23

Seres Therapeutics' Balancing Act: Breakthrough IP And Financing Concerns

Jan 30

Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 30% Price Drop

Dec 18

Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 27% Price Drop

Aug 31

Some Seres Therapeutics, Inc. (NASDAQ:MCRB) Analysts Just Made A Major Cut To Next Year's Estimates

Mar 02

Rock star Growth Puts Seres Therapeutics (NASDAQ:MCRB) In A Position To Use Debt

Dec 27

Seres Therapeutics Molecular Data On SER-109 Looks Good

Oct 04

Seres Therapeutics: Here We Go Again

Sep 09

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: MCRB şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: MCRB şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Seres Therapeutics Piyasaya Karşı Temettü Getirisi

MCRB temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (MCRB)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.4%
Sektör Ortalaması (Biotechs)	1.9%
Analist tahmini (MCRB) (3 yıla kadar)	0%

Önemli Temettü: MCRB şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, MCRB şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: MCRB şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: MCRB herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Seres Therapeutics Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

Lucien Selce and MKT Capital Issue Open Letter to Board of Seres Therapeutics Regarding Reported Engagement with Nestlé

Seres Therapeutics' Strategic Sale Of Vowst Warrants A Rating Upgrade

Seres Therapeutics, Inc. Announces Topline Clinical Data from Cohort 2 of its SER-155 Phase 1b Placebo-Controlled Study in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

First half 2024 earnings released: US$0.49 loss per share (vs US$0.20 loss in 1H 2023)

Consensus EPS estimates upgraded to US$0.85 loss

Seres Therapeutics, Inc. announced that it expects to receive $15.000001 million in funding from Société des Produits Nestlé S.A.

Seres Therapeutics, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 44% But Investors Aren't Buying For Growth

Nestle's Health Unit to Take Full Control of Microbiota-Based Therapeutic

New minor risk - Market cap size

Price target decreased by 14% to US$6.20

First quarter 2024 earnings released: US$0.28 loss per share (vs US$0.56 loss in 1Q 2023)

Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 46% But Investors Aren't Buying For Growth

Seres Therapeutics, Inc. to Report Q1, 2024 Results on May 08, 2024

Seres Therapeutics Receives Non-Compliance Letter from The Nasdaq Stock Market LLC Related to Nasdaq Listing Rule 5450(a)(1)

New minor risk - Market cap size

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT

Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet

Consensus revenue estimates decrease by 63%, EPS upgraded

New minor risk - Financial position

Full year 2023 earnings: EPS exceeds analyst expectations

No longer forecast to breakeven

Seres Therapeutics Appoints Marella Thorell as Executive Vice President

Price target increased by 7.7% to US$9.02

Price target increased by 15% to US$9.80

Seres Therapeutics' Balancing Act: Breakthrough IP And Financing Concerns

Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155

Forecast to breakeven in 2026

Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 30% Price Drop

Consensus EPS estimates upgraded to US$0.98 loss, revenue downgraded

Price target decreased by 13% to US$8.54

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Seres Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023

New minor risk - Share price stability

Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 27% Price Drop

Consensus EPS estimates fall by 34%

Seres Therapeutics (NASDAQ:MCRB) Has Debt But No Earnings; Should You Worry?

Second quarter 2023 earnings: EPS misses analyst expectations

Second quarter 2023 earnings: EPS misses analyst expectations

Price target decreased by 7.6% to US$10.17

Seres Therapeutics, Inc. and Nestle Health Science Present Late-Breaking Data on VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection in Adults, at ASM Microbe 2023

Seres Therapeutics, Inc. and Nestlé Health Science Announce U.S. Commercial Availability of VOWST™

Consensus EPS estimates upgraded to US$0.96 loss

Seres Therapeutics Reports SER-155 Phase 1b Cohort 1 Results Showing Successful Drug Bacteria Engraftment and Substantial Reduction in Pathogen Domination in the Gastrointestinal Microbiome

First quarter 2023 earnings released: US$0.56 loss per share (vs US$0.61 loss in 1Q 2022)

Consensus estimates of losses per share improve by 13%

Price target decreased by 11% to US$11.00

Full year 2022 earnings: EPS and revenues miss analyst expectations

Seres Therapeutics' Investigational Ser-109 Ecospor Iv Study Data Publishes in Jama Network Open

Seres Therapeutics, Inc. Announces Initiation of Enrollment in SER-155 Phase 1B Study Cohort 2 in Individuals Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Insufficient new directors

Seres Therapeutics, Inc. Announces the Appointment of Claire M. Fraser, Ph.D., to Its Board of Directors

Is Seres Therapeutics (NASDAQ:MCRB) Weighed On By Its Debt Load?

Consensus forecasts updated

Price target increased to US$14.33

Seres Therapeutics Announces FDA Acceptance of Biologics License Application for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection for Priority Review

Seres Therapeutics, Inc. Announces the Publication of Phase 3 Clinical Data in the Journal of the American Medical Association

Seres Therapeutics Announces Completion of Rolling BLA Submission to FDA for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection

Estimating The Fair Value Of Seres Therapeutics, Inc. (NASDAQ:MCRB)

Seres Therapeutics: What The Market Is Missing

Consensus revenue estimates increase by 16%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Seres Therapeutics GAAP EPS of -$0.70 misses by $0.10, revenue of $1.22M

Seres Therapeutics: The Good And The Challenging

Seres Therapeutics stock slips on $100M stock offering

Is Seres Therapeutics (NASDAQ:MCRB) Using Too Much Debt?

Seres Therapeutics: As Biotech Fades The Case For Seres Investment Strengthens

Seres Therapeutics, Inc. Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open-Label Study in Recurrent C. Difficile Infection

Seres Therapeutics Presents Phase III Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting

Seres Therapeutics to Present Data on Investigational Microbiome Therapeutic Ser-109 for Recurrent C. Difficile Infection At the Digestive Disease Week (Ddw) Annual Meeting

Consensus revenue estimates fall by 64%

Price target decreased to US$17.57

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Seres Therapeutics, Inc., Annual General Meeting, Jun 22, 2022

Consensus revenue estimates fall by 30%